Raymond James & Associates’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-101,006
| Closed | -$1.04M | – | 3931 |
|
|
2023
Q4 | $1.04M | Buy |
101,006
+3,018
| +3% | +$31.1K | ﹤0.01% | 2480 |
|
|
2023
Q3 | $770K | Buy |
97,988
+5,547
| +6% | +$43.6K | ﹤0.01% | 2608 |
|
|
2023
Q2 | $923K | Buy |
92,441
+24,430
| +36% | +$244K | ﹤0.01% | 2508 |
|
|
2023
Q1 | $604K | Buy |
68,011
+16,980
| +33% | +$151K | ﹤0.01% | 2786 |
|
|
2022
Q4 | $560K | Sell |
51,031
-48
| -0.1% | -$527 | ﹤0.01% | 2811 |
|
|
2022
Q3 | $666K | Buy |
51,079
+9,800
| +24% | +$128K | ﹤0.01% | 2651 |
|
|
2022
Q2 | $523K | Buy |
+41,279
| New | +$523K | ﹤0.01% | 2877 |
|